Tag: 2019
Annual Report 2021
Annual Report 2020
Annual Report 2019
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT…
ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019
Geneva, Switzerland and Boston, MA –December 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…
ObsEva Announces Third Quarter 2019 Financial Results
– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the…
Q3 Report 2019
Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint
Company to Discontinue Current Nolasiban IVF Program Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:…
ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019
Geneva, Switzerland and Boston, MA –November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…